Bayer is planning to sell its animal health business as major private equity firms including KKR and CVC Capital Partners consider making bids, according to sources. Bayer is under pressure to restructure its business amid investor doubts about the US$63bn takeover of Monsanto.
The unit may also draw interest from other private equity firms including Advent International, Blackstone Group, EQT Partners and Permira as well as industry players. The business could fetch as much as €8bn (US$9bn). The sale isn’t expected to begin until the second quarter of the year.
Bayer has appointed an accounting firm and advisers to prepare financial data ahead of the potential sale. Spinning off the business into a publicly traded company is also an option if bids come in too low, according to Bloomberg.
A spokesman for Bayer declined to comment. Representatives for KKR, EQT, Blackstone, Permira, CVC and Advent also declined to comment.